Thymitaq data

AGPH presented interim Phase II results of its Thymitaq thymidylate synthase (TS) inhibitor, showing anti-tumor activity in several solid tumors. TS is an enzyme required for sustained proliferation of cancer cells.

According to a report on six small Phase II trials presented at the American Association of Cancer Research in Fort Myers, Fla., stabilization or reduction in measurable malignant disease has occurred in 59 of 78 evaluable patients. ...